Introduction
Peroxisome proliferator-activated receptors (PPARs) are transcriptional factors that have considerable influence on important molecular events in normal and cancer cells (Kliewer et al., 1999; Michalik et al., 2004) . The possibility of an interaction between various PPARs was raised by study results showing that PPARbeta/delta (PPAR-b/d) overexpression inhibits the activities of PPAR-gamma (PPAR-g) and those of PPAR-alpha (PPAR-a) in nontransformed normal monkey kidney CV-1 cells and mouse NIH 3T3 fibroblasts (Shi et al., 2002) . Other studies, however, have challenged this concept of PPAR-b/d influence on the activation of PPAR-g or PPAR-a because of findings that PPAR-g or PPAR-a activation by synthetic ligands was not significantly affected in PPARb/d-null cells (Peters et al., 2003; Matsusue et al., 2004) . While these conflicting findings might be secondary to differences between the experimental models used (e.g., overexpression vs knockout models), another important explanation to explore is that findings with the use of synthetic ligands might not represent what occurs biologically with the natural ligands of PPARs that are formed intracellularly. Oxidative metabolites of arachidonic and linoleic acids are well-known natural ligands of PPARs (Chawla et al., 2001 ) that can be used to evaluate whether such interaction between PPARs occurs intracellularly as a part of biologic signaling pathways.
To examine these important questions -whether PPAR-b/d interacts with other PPARs and whether this interaction between PPAR-b/d and other PPARs is relevant to the signaling of oxidative metabolites of polyunsaturated fatty acids -we used experimental models of both PPAR-b/d gain and loss of function in colon cancer cells that express both PPAR-g and PPARb/d (Sarraf et al., 1998; He et al., 1999; Gupta et al., 2000) . These complementary experimental models allowed us to examine whether PPAR-b/d interaction with PPAR-g is related to experimental model differences that might have accounted for the conflicting results observed previously by others.
For a natural intracellular PPAR-b/d ligand, we used 13-S-hydroxyoctadecadienoic acid (13-S-HODE), the primary product of 15-lipoxygenase-1 (15-LOX-1) metabolism of linoleic acid, which binds to and modulates the activity of PPAR-b/d . 13-S-HODE also activates PPAR-g when it is exogenously added in micromolar concentrations (10-30 mM) to the culture medium of cells, including colon cancer cells (Nagy et al., 1998; Bull et al., 2003; Nixon et al., 2003) . Thus, the question arises whether 13-S-HODE binding to PPAR-b/d might influence 13-S-HODE activation of PPAR-g. According to the current literature, however, 15-LOX-1 endogenous formation of 13-S-HODE activates PPAR-g in mouse macrophages and fibroblasts (Huang et al., 1999) but not in human colon cancer cells (Nixon et al., 2003) . Therefore, to address this conflict in the previously reported data, we initially examined whether the endogenous formation of 13-S-HODE by 15-LOX-1 can activate PPAR-g in colon cancer cells. Our findings in this study demonstrated that PPAR-b/d suppresses PPAR-g activity in both PPAR-b/d gain and loss of function models, and that the oxidative metabolites of polyunsaturated fatty acids, as in the case of 13-S-HODE, modulate this interaction to activate PPAR-g.
Results

15-LOX-1 formation of endogenous 13-S-HODE increases PPAR-g activity in colon cancer cells
The adenovirus vector that carries human 15-LOX-1 cDNA (Ad-15-LOX-1) efficiently expressed 15-LOX-1 in colon cancer cells. Ad-15-LOX-1 transfection induced expression of 15-LOX-1 in HCT-116 and LoVo colon cancer cells, whereas 15-LOX-1 was not expressed in control cells transfected with the same adenoviral vector that carried the LacZ gene (Ad-LacZ) instead of 15-LOX-1 (Figures 1a and b) . Expression of 15-LOX-1 increased 13-S-HODE levels in colon cancer cells ( Figures 1c and d) ; adding linoleic acid to the culture medium enhanced 13-S-HODE production in the 15-LOX-1-transfected cells, whereas adding caffeic acid (a 15-LOX-1 inhibitor) in a concentration that specifically inhibits 15-LOX-1 enzymatic activity (Shureiqi et al., 2000) reduced their 13-S-HODE production (Figures 1c and d) . 13-S-HODE formation in LoVo cells, which express 15-LOX-1, increased in a manner that was dependent on the concentrations of linoleic acid added to the medium (Po0.0001). Caffeic acid significantly reduced 13-S-HODE formation in Ad-15-LOX-1-transfected LoVo cells (Po0.0001). Similar effects (increased 13-S-HODE formation with Ad-15-LOX-1 transfection and decreased 13-S-HODE formation with caffeic acid) occurred in HCT-116 cells (Po0.0001).
Next, we examined whether 15-LOX-1 expression in colon cancer cells affects PPAR-g transcriptional activity, which we monitored with a PPAR-g-dependent luciferase reporter construct, (Aox) 3 -TK-Luc, with and without ectopic PPAR-g expression (Huang et al., 1999) . 15-LOX-1 expression markedly increased PPAR-g activity, and this activation increased further with the addition of linoleic acid to the culture medium (Figures 1e and f) . In LoVo cells, 15-LOX-1 transfection increased PPAR-g activity by a factor of 4 or more (Po0.0001). Linoleic acid increased this activation in a concentration-dependent manner (Po0.0001), whereas Ad-LacZ transfection, either alone or with linoleic acid supplementation, did not increase PPAR-g activity. Similar effects occurred in HCT-116 cells: 15-LOX-1 significantly increased PPAR-g activity, and linoleic acid further enhanced this activity (Po0.0001). Transfection of both LoVo and HCT-116 cells with PPAR-g dominant-negative expression vector markedly inhibited PPAR-g activity relative to that in cells transfected with either control vector (empty vector) or the same vector that carried PPAR-g cDNA (Po0.0001 for both LoVo and HCT-116 cells) ( Supplementary Figures 1 and 2) .
We also tested whether 15-LOX-1 enzymatic activity was involved in the increased PPAR-g activity after 15-LOX-1 transfection. We inhibited 15-LOX-1 enzymatic activity with caffeic acid, which significantly reduced PPAR-g activity in the 15-LOX-1-transfected cells Ad-LacZ and cultured in medium supplemented with linoleic or caffeic acid as follows: LA0, no additional linoleic acid added; LA5, 5 mM linoleic acid added; LA10, 10 mM linoleic acid added; and CAF2.2, 2.2 mM caffeic acid added. Cells were harvested 48 h after transfection for measuring 13-S-HODE levels by enzyme immunoassay. Values shown are the means7s.d.'s of triplicate experiments. (e and f) Effects of 15-LOX-1 expression on PPAR-g activity. LoVo (e) and HCT-116 (f) cells were first transfected with either Ad-15-LOX-1 or Ad-LacZ; cells were transfected with the luciferase reporter system (Aox) 3 -TK-Luc 24 h later and with either pcDNA3.0-PPAR-g expression vector or control vector (empty pcDNA3.0). PPAR-g transcriptional activity was measured 24 h after the second transfection and normalized to b-galactosidase activity (relative to 100 000 b-galactosidase units). The culture medium was supplemented with linoleic acid as indicated. pcDNA3.0-PPAR-g vector transfection is denoted by þ PPAR-g. Values shown are the means7s.d.'s of triplicate experiments. (g-j) Effects of 15-LOX-1 expression on the expression of PPAR-g endogenous target genes. LoVo (g and i) and HCT-116 (h and j) cells were transfected with Ad-15-LOX-1 or Ad-LacZ, treated with DMSO (Control) or with 2.2-mM caffeic acid and harvested 48 h later. Expression of CD36 and Keratin 20 was measured using real-time PCR (see Materials and methods). The relative expression levels were calculated as the values relative to that of the calibrator sample (Ad-LacZ-transfected cells). Values shown are the means7s.d.'s of triplicate experiments.
15-LOX-1 modulates PPAR-beta/delta suppression of PPAR-gamma X Zuo et al (Po0.0001; data not shown). 15-LOX-1 inhibition had no statistically significant effects on PPAR-g activation in Ad-LacZ-transfected cells (P ¼ 0.55).
We later tested the effect of 15-LOX-1 expression on two endogenous PPAR-g target genes (CD36 and Keratin 20) to confirm the biologic relevance of our earlier findings. Among the PPARs, PPAR-g selectively induces Keratin 20 expression in colon cancer cells (Gupta et al., 2001 ). 15-LOX-1 increased CD36 and Keratin 20 expression in LoVo and HCT-116 cells, and inhibition of 15-LOX-1 enzymatic activity suppressed that increased expression. Ad-15-LOX-1 transfection of LoVo cells increased the expression of CD36 by a factor of 2.5 (Po0.0001) (Figure 1g ) and Keratin 20 by a factor of 3 (Po0.0001) relative to that in the control (Ad-LacZ)-transfected cells (Figure 1i ). Inhibition of 15-LOX-1 enzymatic activity blocked those increases in expression levels. Similarly, in HCT-116 cells, 15-LOX-1 increased the expression of both CD36 (P ¼ 0.0003) and Keratin 20 (P ¼ 0.0002), whereas inhibiting 15-LOX-1 enzymatic activity blocked these effects (Figures 1h and j) .
15-LOX-1 expression had no effect on PPAR-g expression in either HCT-116 or LoVo cells (data not shown), demonstrating that 15-LOX-1 did not activate PPAR-g transcription by increasing the level of PPAR-g expression.
PPAR-b/d expression modulates PPAR-g activity in colorectal cancer cells
We used experimental models of both PPAR-b/d loss and gain of function in colon cancer cells that express both PPAR-g and PPAR-b/d to examine whether an interaction exists between PPAR-b/d and PPAR-g. As colon cancer cells overexpress PPAR-b/d (He et al., 1999; Gupta et al., 2000) , we initially evaluated this relationship between PPAR-b/d and PPAR-g using experimental models of PPAR-b/d downregulation. We used the small interfering RNA ( 'Probe only' is the negative control. Fixed amounts of RXR-a (0.5 ml of 58.3-mg/ml lysate) and PPAR-g (g; 0.5 ml of 56.4-mg/ml lysate) were used. PPAR-b/ d (b/d) was added in increasing amounts (1.5, 3.0, 6.0, and 9.0 ml of 53.9-mg/ml lysate), as indicated by the black wedges. PPAR-g monoclonal antibody was added for supershift assays. 15-LOX-1 modulates PPAR-beta/delta suppression of PPAR-gamma X Zuo et al cells increased PPAR-g activity to a higher level in HCT-116 than in KO1 cells (P ¼ 0.0018) (Figure 3i ). These data questioned whether 13-S-HODE acts as a binding ligand for PPAR-g. Scintillation proximity assays of the direct binding of 13-S-HODE to PPAR-g showed that 13-S-HODE has no binding affinity for PPAR-g (Figure 3j ). These findings did not support the notion that the interaction between PPAR-b/d and PPAR-g is secondary to competition for ligand binding.
We then examined whether PPAR-b/d inhibits PPAR-g DNA binding as a transcriptional factor. PPARs bind DNA to activate transcription by forming heterodimers with retinoid X receptor alpha (RXR-a) (Kliewer et al., 1992; Gearing et al., 1993) . Thus, we assessed PPAR-b/d ability to inhibit binding of the PPAR-g/RXR-a heterodimer to the PPAR-g DNA recognition sequence in the acyl-coA oxidase gene promoter (ACO) (He et al., 1999) in electrophoretic 15-LOX-1 modulates PPAR-beta/delta suppression of PPAR-gamma X Zuo et al mobility-shift (EMSA) and supershift assays. The PPAR response element ACO binds efficiently to PPAR-a and PPAR-g but not to PPAR-b/d (He et al., 1999) . Although PPAR-b/d binding to ACO at various concentrations (4-24 mg/ml of EMSA incubation solution) was weaker than that of PPAR-g at a much lower concentration (1.4 mg/ml of EMSA incubation solution), PPAR-b/d reduced the PPAR-g/RXR-a heterodimer's binding to the ACO sequence at high concentrations in EMSA and supershift assays (Figure 3k ), a condition that would simulate PPAR-b/d overexpression in cancer cells (He et al., 1999) . We also quantitatively examined the effects of PPAR-b/d on PPAR-g binding to the peroxisome proliferator response element (PPRE) (Renard et al., 2001) (Figures 4b and c) .
We also examined whether the effects of 15-LOX-1 on PPAR-g activation were mediated through its main product, 13-S-HODE. We supplemented Ad-LacZ (control)-transfected colon cancer cells with either 13-S-HODE or linoleic acid and compared PPAR-g binding to the PPRE in these cells with that in cells expressing 15-LOX-1 via Ad-15-LOX-1. We found that 13-S-HODE, but not linoleic acid (the parent compound before 15-LOX-1 metabolism), significantly increased PPAR-g binding to the PPRE in both HCT-116 and LoVo cells (P ¼ 0.007 and 0.004, respectively). 13-S-HODE significantly increased PPAR-g binding to the PPRE in Ad-LacZ-transfected (compared with controltreated) HCT-116 and LoVo cells (P ¼ 0.0006 and 0.04, respectively) (Figures 4d and e) . The level of increase in PPAR-g binding to PPRE was similar to levels in Ad-15-LOX-1-transfected cells. These findings indicated that 15-LOX-1 effects on PPAR-g are mediated through 13-S-HODE formation.
PPAR-b/d also inhibited the 15-LOX-1-mediated increase of PPAR-g activity, as measured using the 
15-LOX-1 induces apoptosis via downregulation of PPAR-b/d and activation of PPAR-g
The expression of 15-LOX-1 inhibited the growth of HCT-116 and LoVo colorectal cancer cells by inducing apoptosis, as confirmed by caspase-3 activity and DNA fragmentation assays (Figures 5a-d) . 15-LOX-1 expression increased casapase-3 activity by a factor of approximately 2 relative to that in LacZ-transfected cells (Figures 5c and d) . Casapase-3 activity was significantly higher in Ad-15-LOX-1-transfected cells than it was in Ad-LacZ-transfected cells (Po0.002 for LoVo; P ¼ 0.0265 for HCT-116). Furthermore, ectopic expression of PPAR-b/d or PPAR-g dominant-negative significantly inhibited apoptosis induction in HCT-116 and LoVo cells (Figures 5e and f) . 15-LOX-1 expression significantly increased caspase-3 activity, whereas PPAR-b/d overexpression or PPAR-g dominant-negative expression significantly reduced caspase-3 activity in 15-LOX-1-transfected cells (P ¼ 0.0072 for LoVo; P ¼ 0.0215 for HCT-116). Caspase-3 activity was similar in cells cotransfected with Ad-15-LOX-1 and either PPAR-b/d or PPAR-g dominant-negative vectors (P ¼ 0.4166 for LoVo; P ¼ 0.5512 for HCT-116). Our results demonstrated for the first time that endogenous formation of 13-S-HODE by 15-LOX-1 promotes PPAR-g activation in human colon cancer cells. Our following findings confirm that 15-LOX-1 activation of PPAR-g occurred via 13-S-HODE production: (a) expressed 15-LOX-1 significantly increased 13-S-HODE formation in colon cancer cells, (b) adding linoleic acid (the substrate of 13-S-HODE) significantly increased PPAR-g activation in colon cancer cells that express, but not in those that do not express, 15-LOX-1, and (c) adding caffeic acid at concentrations known to inhibit specifically 15-LOX-1 enzymatic activity (Shureiqi et al., 2000) reduced both 13-S-HODE formation and PPAR-g activation. These results indicate that 15-LOX-1 expression induced PPAR-g activation via its enzymatic activity (i.e., production of 13-S-HODE).
These findings concur with prior results obtained from activating PPAR-g via exogenous 13-S-HODE in various cell lines, including colon cancer cell lines (Nagy et al., 1998; Bull et al., 2003) , and obtained from expressing 15-LOX-1 in mouse cell lines (Huang et al., 1999) . However, our results that endogenous formation of 13-S-HODE in colon cancer cells activates PPAR-g counters previously reported findings in colon cancer cell lines (Nixon et al., 2003) . This discrepancy may result from the use of different assays. The previous study (Nixon et al., 2003 ) measured 15-LOX-1 effects on activation of the PPAR-g ligand-binding domain, whereas we directly measured PPAR-g transcriptional activity. We have confirmed that our measured 15-LOX-1 effects on PPAR-g activity via the luciferase reporter system (AOx) 3 -TK-Luc were specific for PPAR-g activity by coexpressing 15-LOX-1 with PPAR-g, PPAR-g dominant negative, or both. Ectopic PPAR-g expression 
15-LOX-1 modulates PPAR-beta/delta suppression of PPAR-gamma
X Zuo et al increased the measured luciferase activity through the (AOx) 3 -TK-Luc system; this increase in luciferase activity was thus attributed to PPAR-g. The increased luciferase activity resulting from ectopic PPAR-g expression was further amplified (3-5-fold) by the expression of 15-LOX-1, indicating that 15-LOX-1 increased PPAR-g activity. The measured increase in PPAR-g activity by 15-LOX-1 expression through the (Aox) 3 -TK-Luc system was strongly suppressed by the ectopic expression of PPAR-g dominant negative; this finding further confirmed that 15-LOX-1 expression specifically increased PPAR-g activity. Furthermore, we found that 15-LOX-1 expression markedly increased the endogenous expression of the PPAR-g target genes CD36 and Keratin 20 in colon cancer cells. PPAR-g is the only member of the PPAR family that promotes Keratin 20 expression in colon cancer cells (Gupta et al., 2001) . These findings also confirmed that 15-LOX-1 expression in colon cancer cells increases PPAR-g activity. We previously found that ectopic 15-LOX-1 expression in colorectal cancer cells inhibited PPAR-b/d activity . Therefore, our findings indicate that 15-LOX-1 expression has a differential effect on PPARs, promoting PPAR-g activity while inhibiting PPAR-b/d. CD36 can induce apoptosis in nonendothelial cells (Jimenez et al., 2000; Rusinol et al., 2000; Febbraio et al., 2001) , and Keratin 20 expression is associated with intestinal epithelial cell differentiation (Calnek and Quaroni, 1993; Moll et al., 1993) . Therefore, our findings that 15-LOX-1 promoted the expression of PPAR-g target genes such as CD36 and Keratin 20, which contribute to cell maturation and apoptosis, indicate possible downstream molecular events that are modulated by 15-LOX-1 signaling via PPAR-g to inhibit tumorigenesis (Sarraf et al., 1998; Shureiqi et al., 1999 Shureiqi et al., , 2003 Shureiqi and Lippman, 2001; Girnun et al., 2002; Osawa et al., 2003; Nixon et al., 2004) .
PPAR-b/d inhibited the activities of PPAR-g and PPAR-a in experimental models of PPAR-b/d overexpression in nontransformed normal monkey kidney CV-1 cells and mouse NIH 3T3 fibroblasts (Shi et al., 2002) . In contrast, exogenous synthetic ligands of the PPARs produced no significant alterations in PPAR-g activity in experimental models of PPAR-b/d or PPARa knockout (Peters et al., 2003; Matsusue et al., 2004) . These contradictory results may reflect differences between the experimental models used, but the exact causes remained to be defined. Therefore, we examined whether PPAR-b/d expression can influence PPAR-g activity in models of PPAR-b/d loss and gain of function. We found that PPAR-b/d downregulation with the siRNA approach increased PPAR-g activation in colon cancer cells. The effects of PPAR-b/d expression on PPAR-g activity were specific to PPAR-b/d because we found that downregulation of PPAR-a expression failed to influence PPAR-g activity.
In Regarding the possibility that the interaction might be mediated through PPAR-b/d competing with PPAR-g for ligand binding, we found that PPAR-g activation by troglitazone, a specific PPAR-g ligand (Gupta et al., 2001) , was inhibited in association with PPAR-b/d expression and increased in association with PPAR-b/d downregulation. These finding indicates that PPAR-b/d inhibition of PPAR-g activity is unlikely to be mediated via competition for ligand binding because PPAR-g activation by a specific PPAR-g ligand was influenced by the expression of PPAR-b/d, which does not bind to troglitazone.
We further examined the possibility of competition between PPAR-b/d and PPAR-g for ligand binding with regard to 13-S-HODE, a natural ligand that has been reported to bind to both PPAR-g (Nagy et al., 1998) and PPAR-b/d . Unlike the case with troglitazone, downregulation of PPAR-b/d failed to increase PPAR-g activation by 13-S-HODE. This finding is directly opposed to what would be expected if the PPAR-b/d and PPAR-g interaction were mediated via binding to common ligands, in which case decreased PPAR-b/d expression should increase PPAR-g binding and activation by 13-S-HODE. This finding also raised the possibility that 13-S-HODE does not activate PPAR-g through direct binding but does so indirectly through PPAR-b/d downregulation. Indeed, KO1 cells that lack PPAR-b/d expression had significantly lower PPAR-g activation with 15-LOX-1 expression than did their parental colon cancer cell line, which expresses PPAR-b/d. This further supported the concept that 13-S-HODE, the main product of 15-LOX-1, depends on PPAR-b/d downregulation, at least in part, to activate PPAR-g indirectly. We previously reported that the K d for 13-S-HODE binding to PPAR-b/d is 10.8 mM (Shureiqi et al., 2003) . The 13-S-HODE binding constant to PPAR-g has not been formally determined but has been estimated to be in the 10-20-mM range (Nagy et al., 1998) . We measured the 13-S-HODE binding constant to PPAR-g in a scintillation proximity assay and found that 13-S-HODE has a negligible affinity to PPAR-g even in concentrations reaching 100 mM. These findings further support the concept that 13-S-HODE does not activate PPAR-g through direct binding but more likely through an indirect mechanism such as downregulating PPAR-b/d.
We next examined the possibility that the interaction between PPAR-b/d and PPAR-g is mediated by PPARb/d modulating PPAR-g DNA binding. For this analysis, we used in vitro gel-shift and supershift assays and in vivo ChIP assays in colon cancer cells with and without PPAR-b/d expression. For the in vitro EMSA and supershift assays, we used the PPAR response element ACO, which preferentially binds more to PPAR-a and PPAR-g than to PPAR-b/d (He et al., 1999) . PPAR-b/d at various concentrations (4-24 mg/ml of EMSA incubation solution) bound weakly to ACO, whereas PPAR-g bound strongly to ACO at a much lower concentration ( In later studies, using ChIP assays, we found that PPAR-b/d can bind to the PPAR-g target DNA sequence in the LPL promoter and that this binding can be inhibited by 13-S-HODE but not by its parent compound, linoleic acid. These findings support the conclusion that PPAR-b/d inhibits PPAR-g binding to its DNA recognition sites and that this interaction can be modulated through 13-S-HODE, which downregulates PPAR-b/d expression.
Our findings that PPAR-b/d suppressed PPAR-g activity conflict with those of another group, who studied the effects of synthetic PPAR ligands in nontransformed PPAR-b/d-null cells (Peters et al., 2003; Matsusue et al., 2004) . These differences might be attributed to variation in the experimental models used, including the basal levels of PPAR-b/d expression in different cells (e.g., in transformed vs nontransformed cells). Cancer cells, in contrast with normal cells, commonly overexpress PPAR-b/d (He et al., 1999; Gupta et al., 2000; Stephen et al., 2004) The biologic significance of 15-LOX-1 effects on the interaction between PPAR-b/d and PPAR-g in colon cancer cells was further supported by our findings that 15-LOX-1 expression induced apoptosis and that these effects depended on modulation of the interaction between PPAR-b/d and PPAR-g. We previously found that colorectal cancer cells lack 15-LOX-1 expression and that exogenous replacement of the 15-LOX-1 product 13-S-HODE in colorectal cancer cells induces apoptosis (Shureiqi et al., 1999) . The findings from our new studies demonstrate for the first time that genetically reconstituting enzymatically active 15-LOX-1 by ectopic expression in colorectal cancer cells induces apoptosis. Furthermore, the ability of 15-LOX-1 to induce apoptosis in these cells was inhibited by the ectopic expression of either PPAR-g dominant negative or PPAR-b/d. These findings demonstrate, also for the first time, that 15-LOX-1 induction of apoptosis can be mediated by modulating PPAR-b/d suppressive effects on PPAR-g.
In conclusion, our present and previous findings support a new model of the 15-LOX-1 signaling pathway in colon cancer cells (Figures 5g and h) , which is an example of the ability of oxidative metabolism of polyunsaturated fatty acids to modulate the interaction between PPAR-b/d and PPAR-g. In colon cancer cells, 15-LOX-1 expression is lost and PPAR-b/d is overexpressed, resulting in the suppression of PPAR-g transcriptional activity (Figure 5g ). However, restoring 15-LOX-1 expression produces 13-S-HODE, which downregulates PPAR-b/d expression and thus promotes PPAR-g activity ( Figure 5h ). As with any conceptual model, our proposed model may somewhat oversimplify highly complex interactive biologic events. Future studies will be needed to further elucidate how the signaling of polyunsaturated fatty acid oxidative metabolic pathways modulates the interaction between PPARs to influence important biologic events such as apoptosis in cells.
PPAR-g activity assays PPAR-g transcriptional activity was measured by transfecting cells with the PPAR-g-dependent reporter construct (AOx) 3 -TK-Luc (0.4 mg/well of a 24-well plate) (Huang et al., 1999) using Lipofectamine 2000 (Invitrogen) . The pSV-b-galactosidase vector (0.2 mg/well of a 24-well plate) was cotransfected for normalization to b-galactoside activity. Cells were harvested at the indicated times and lysed, and then luciferase activity was measured using a luciferase assay kit (Promega). Luciferase activity levels were normalized to b-galactosidase activity, which was measured using a commercial kit (Invitrogen).
siRNA transfection Cells were cultured to 50-70% confluence and then transfected with 100 nmol of a pooled mixture of four SMARTselected siRNA duplexes (SMARTpool; Dharmacon Inc., Lafayette, CO, USA) for PPAR-b/d, PPAR-a, or a nonspecific control 15-LOX-1 modulates PPAR-beta/delta suppression of PPAR-gamma X Zuo et al siRNA (siGLO RISC-Free siRNA; Dharmacon) using Lipofectamine 2000.
Quantitative real-time reverse transcriptase-PCR (RT-PCR)
Total RNA was extracted from cells using TRI reagent (Molecular Research Center Inc., Cincinnati, OH, USA). The isolated RNA was size fractionated by electrophoresis in a 1% agarose-formaldehyde gel, stained with ethidium bromide, and confirmed to be of adequate quality (clear RNA bands for 18S, 28S, and 5S; 28S:18S of 2:1). Extracted RNA was quantified using an RNA quantitation kit (RiboGreen; Molecular Probes Inc., Eugene, OR, USA). A 500-ng aliquot of each RNA sample was reverse transcribed in a 20-ml reaction using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA). The real-time PCR was carried out in 25 ml of a reaction mixture containing 1 ml of cDNA (25 ng/ml), 12.5 ml of 2Â TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA), and 1.25 ml of primer and probe mixture (Applied Biosystems). Real-time PCR assays were performed in triplicate using a 7300 real-time PCR system (Applied Biosystems) with the following program: 501C for 2 min, 951C for 10 min, 40 cycles at 951C for 15 s, and at 601C for 1 min. A sequence detection program calculated a threshold cycle number (C T ) at which the probe cleavage-generated fluorescence exceeded the background signal (Pfaffl, 2001 ).
Measurement of relative RNA expression level
We calculated the relative RNA expression level using a comparative C T method (Pfaffl, 2001 (Pfaffl, 2001) . Thus, the relative RNA expression level of a gene is a unitless number relative to that of the calibrator sample (Yu et al., 2003) . Relative RNA expression calculations were performed using commercial software (SDS V1.2; Applied Biosystems).
Scintillation proximity assays of 13-S-HODE binding to PPAR-g These assays were performed as described previously with the use of [ 3 H]rosiglitazone as the radiolabeled ligand for PPAR-g.
In vitro transcription/translation
The full-length proteins PPAR-g, PPAR-b/d, and RXR-a were produced by in vitro transcription-coupled translation of PCR products using TNT T7 Quick-coupled transcription and translation systems (Promega) and PCR-generated DNA templates. The PCR primers used were as described previously (He et al., 1999) . PPAR-g, PPAR-b/d, and pCMV6-XL4-RXR-a (OriGene) vectors containing full-length cDNA of the three genes (PPAR-g, PPAR-b/d, and RXR-a) were used as PCR templates. The translation products were verified by Western blotting.
Gel EMSA
To study the mechanisms of PPAR-b/d's effects on PPAR-g's transcriptional activity, the PPAR-g DNA recognition sequence from the acyl-coA oxidase gene promoter ACO was used (He et al., 1999) . The double-stranded oligonucleotide of the ACO sequence was formed by annealing 5 0 -GCGGAC CAGGACAAAGGTCACGTTC-3 0 and 5 0 -CGAACGTGAC CTTTGTCCTGGTCCG-3 0 . The resulting double-stranded oligonucleotide was 32 P-labeled with T4 polynucleotide kinase (Promega). RXR-a (0.5 ml of 58.3-mg/ml lysate), PPAR-g (0.5 ml of 56.4-mg/ml lysate), and/or PPAR-b/d (1.5, 3.0, 6.0, or 9.0 ml of 53.9-mg/ml lysate) derived from in vitro-translated proteins were mixed with the probe (40 000 c.p.m.) and gel-shift binding buffer (Promega) for 25 min on ice. The DNA-protein complexes were identified as being resolved from the free probe by electrophoresis at 41C on 5% polyacrylamide gel in 1 Â Tris borate-EDTA buffer (pH 8.3). For gel supershift assays, 2 ml of 10Â PPAR-g monoclonal antibody (Santa Cruz) was added to each sample and incubated at room temperature for 20 min, and then on ice for another 25 min.
Chromatin immunoprecipitation
To study PPAR-g binding to its target genes in vivo, we used a previously validated ChIP assay for PPAR-g binding to the human LPL promoter (Fajas et al., 2002a, b) Cells were crosslinked 48 h after the designated transfections by adding formaldehyde to the culture medium to a final concentration of 1% and incubating for 10 min at 371C. ChIP assays were performed using a commercial assay kit according to the manufacturer's protocol (Upstate Cell Signaling Solutions, Waltham, MA, USA). Chromatin was immunoprecipitated using a specific monoclonal anti-PPAR-g antibody (Santa Cruz). The following primers were used to amplify a 230 bp fragment of the human LPL promoter: 5 0 -GGGCCCCCGGGTAGAGTGG-3 0 (sense) and 5 0 -CACGCCAAGGCTGCTTATGTGACT-3 0 (antisense) using the following parameters: 941C for 3 min and then 941C for 20 s, 601C for 30 s, and 71.51C for 70 s for 25 cycles. The PCR conditions were optimized for the primer set to ensure that the yield of product was within the linear range (data not shown).
Quantitative assay for PPAR-g DNA binding PPAR-g DNA binding was quantified using a PPAR-g transcription factor assay kit (TransAM PPAR-g kit; Active Motif Co., Carlsbad, CA, USA) (Renard et al., 2001) . A PPAR-g-specific antibody is used in this enzyme-linked immunosorbent assay to measure specifically PPAR-g binding to an oligonucleotide containing the PPRE. Nuclear extracts were prepared, and PPAR-g binding to the PPRE was assayed according to the manufacturer's protocol.
Western blot analysis
For Western blotting, protein samples were prepared and subjected to SDS-PAGE under reducing conditions as described previously (Shureiqi et al., 2000) . After transfer, blots were probed with a solution of rabbit polyclonal antibody to human 15-LOX-1 (1:2000) , PPAR-b/d (1:500), or a monoclonal antibody to human PPAR-g-1 (1:300), and then analysed using the enhanced chemiluminescence method.
13-S-HODE measurements
Cells were harvested, and 13-S-HODE was extracted from both the culture medium and cell lysates and then measured using a commercially available enzyme immunoassay kit (Assay Designs Inc., Ann Arbor, MI, USA) (Shureiqi et al., 2000) .
Assessments of apoptosis
Apoptosis was measured by cell imaging and by DNA fragmentation and caspase-3 activity assays. Inverse light (phase-contrast) microscopy was used to assess gross evidence of growth inhibition and apoptosis. Cell morphology images were taken under light microscopy 50 h after the cells' transfection with Ad-15-LOX-1 or Ad-LacZ. Floating and attached cells were harvested 48 h after transfection with Ad-15-LOX-1 or Ad-LacZ, and the DNA fragmentation assay was performed as described previously . For the caspase-3 activity assay, cells were transfected first with Ad-15-LOX-1 or Ad-LacZ, and then 12 h later with pcDNA3.0-PPAR-g dominant-negative vector, pcDNA3.0-PPAR-b/d, or pcDNA3.0 empty vector (control vector). Cells were harvested 36 h after the second transfection, and caspase-3 activity was measured using a commercially available kit (BD Biosciences Clontech, Palo Alto, CA, USA) according to the manufacturer's protocol.
Statistical analyses
For analyses involving the simultaneous consideration of two factors, we performed two-way analyses of variance. Our analyses proceeded as follows: we first tested the interaction effect, and if it was significant, we subsequently performed specific comparisons to investigate which differences were driving this effect, using the Bonferroni adjustment to adjust for the multiple testing problem. This means that if we performed k comparisons, an individual comparison would not be considered significant unless its P-value was less than 0.05/k. If the interaction effect was not significant, we tested the individual main effects. Then, if those were significant, we determined which pairwise comparisons were significant, again adjusting for multiplicities using the Bonferroni correction. For analyses involving single factors, we performed a one-way analysis of variance. If the overall analysis of variance test was significant, then we performed pairwise comparisons, adjusting for multiplicities using the Bonferroni correction. All tests were two-sided and conducted at the Pp0.05 level. All quantitative analyses were carried out on the log-transformed data because we found that the log transformation decoupled the relationship between the mean and variance and accommodated the normal-distributional assumptions underlying the methods. Data were analysed using SAS software (SAS Institute, Cary, NC, USA).
